Every year, approximately 30 million infants are born in regions of Africa at risk for malaria infection. Without specific treatment for these vulnerable infants, malaria can quickly lead to complications and become fatal.
Until now, treatments have only been approved for infants weighing more than 4.5 kilograms, resulting in a significant treatment gap.
On July 8, 2025, Novartis announced that Swissmedic had approved Coartem® Baby (Riamet® Baby) as the first malaria medication specifically for newborns and young infants.
Read More
